CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for GT Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

GT Biopharma Inc
315 MONTGOMERY STREET, 10TH FLOOR
Phone: (310) 551-4020p:310 551-4020 SAN FRANCISCO, CA  94104  United States Ticker: GTBPGTBP
Business Summary
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer (NK) cells. The Company is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Interim Chief Executive Officer MichaelBreen 61 3/2/2022 1/13/2021
Independent Vice Chairman of the Board Bruce J.Wendel 70 11/11/2020 11/11/2020
Chief Financial Officer Alan L.Urban 55 6/3/2024 6/9/2022
Independent Director Charles J.Casamento 78 5/1/2023 5/1/2023
Independent Director RajeshShrotriya 79 1/13/2021 1/13/2021

Business Names
Business Name
Georgetown Translational Pharmaceuticals, Inc.
GTBP
OXIS
Oxis Biotech, Inc.
OXISD

General Information
Number of Employees: 2 (As of 12/31/2023)
Outstanding Shares: 2,234,328 (As of 8/10/2024)
Shareholders: 30
Stock Exchange: NASD
Federal Tax Id: 941620407
Fax Number: (302) 655-5049
Email Address: christiw@oxis.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024